Join the Oncology Voice Network. Join for Free
How Competition Fuels Collaboration in Oncology

How Competition Fuels Collaboration in Oncology


Share This Article


Can rivalry actually unlock true collaboration in cancer drug development? In this episode of the Oncology Voice Network podcast, Dr. Kirk Shepard sits down with Tim Mikhelashvili, CEO and cofounder of Amadea Pharma and the mastermind behind the Medical Innovation Olympics. They challenge conventional wisdom, revealing how competition and recognition can strengthen, not sabotage, teamwork in oncology. Hear the inside story of the Medical Innovation Olympics—where leaders from rival companies present side-by-side, sparking bold ideas and even unexpected partnerships. Tim Mikhelashvili pulls back the curtain on why most collaboration barriers are about people, not science or technology. Discover practical, surprising strategies from the world of sports that help medical teams perform at Olympic levels day after day. Get the truth about bottlenecks that stifle innovation, how transparency and accountability change behaviors, and why measuring real contributions is the game-changer oncology needs. Listen now and join the movement reshaping how oncology leaders compete and win together.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN